In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In a phase 2b trial, efruxifermin significantly improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis, with the 50 mg dose showing the greatest benefit.
The FDA has announced the approval of the semaglutide injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis following promising interim analysis data.
...
A global analysis reveals growing diabetes burden linked to alcohol consumption, with projections pointing to continued increases without targeted intervention. This study was presented at the Endocrine...
A new national analysis reveals that young adult women (ages 18-25) now binge drink at higher rates than men within the same age range, a reversal of previous trends. While heavy drinking remains more...
At the American Association of Clinical Endocrinology 2025 Annual Meeting, Jaime Almandoz, MD, MBA, FTOS, discussed the importance of continuing medical treatment for patients with obesity following...
Nerve blocks administered in the emergency department significantly reduce opioid use in patients with hip fractures, but their effectiveness may wane within 36 hours—before most patients reach surgery....
A new analysis of national mortality data highlights increases in alcohol-related deaths in the United States from 1999 to 2020, underscoring the urgency of addressing this growing public health crisis.
...
In a cohort study, researchers observed a significant decrease in incident reinfection among patients with Hepatitis C who received increased follow-up after achieving sustained virologic response.
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
